Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Forodesine hydrochloride IV: Phase IIb discontinued

BCRX discontinued a Phase IIb trial of IV forodesine due to a lower than expected response rate

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE